Cerebral Inc. agreed to pay over $3.6 million for improper practices related to controlled substance prescriptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback